6-tert-butoxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine | 686344-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-tert-butoxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine
• 英文别名: 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(2-methylpropan-2-yl)oxy]purine
• CAS: 686344-43-4
• 化学式: C₂₁H₁₇Cl₃N₄O
• 分子量: 447.751
• InChiKey: PPNKCVSOPVJBPB-UHFFFAOYSA-N

物化性质

• 沸点：
  590.1±60.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  52.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-chloro-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine 、 potassium tert-butylate 在 乙酸乙酯 、 碳酸氢钠 、 Sodium sulfate-III 、 crude product 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以to give title compound 2A-1 as a yellow oil的产率得到6-tert-butoxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine
  参考文献：
  名称：

  Cannabinoid Receptor Ligands and Uses Thereof

  摘要：

  本文介绍了一种化合物（I）的配方，其作为大麻素受体配体，并且在动物中治疗与大麻素受体介导的疾病相关的用途。

  公开号：

  US20060241120A1

文献信息

• [EN] PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS<br/>[FR] COMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES CANNABINOIDES
  申请人：PFIZER PROD INC

  公开号：WO2004037823A1

  公开（公告）日：2004-05-06

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• Purine compounds and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040092520A1

  公开（公告）日：2004-05-13

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了化学式为（I）的化合物，它们作为大麻素受体配体，并且在动物中治疗与大麻素受体介导的疾病相关的用途。
• Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
  申请人：Pfizer Inc

  公开号：US20040224962A1

  公开（公告）日：2004-11-11

  Pharmaceutical compositions are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗肥胖、超重和强迫性暴饮暴食的药物组合物。这些药物组合物由烟碱受体部分激动剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。
• Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
  申请人：Pfizer Inc

  公开号：US20040224963A1

  公开（公告）日：2004-11-11

  Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗尼古丁依赖或成瘾、烟草依赖或成瘾、减轻尼古丁戒断症状或帮助戒烟或减少烟草使用或药物滥用或其他行为依赖的药物组合物。药物组合物由尼古丁受体部分激动剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。
• Pharmaceutical composition for the prevention and treatment of addiction in a mammal
  申请人：Coe Wadsworth Jotham

  公开号：US20050043327A1

  公开（公告）日：2005-02-24

  Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of alcohol use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compositions are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗酒精或可卡因依赖或成瘾、烟草依赖或成瘾、减轻酒精戒断症状或帮助停止或减轻酒精使用或药物滥用或包括赌博在内的其他行为依赖的药物组合物。药物组合物由阿片受体拮抗剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。